B
KDNY

Bailard’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Bailard’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-5,000
Closed -$100K – 611
2019
Q1 		$100K Buy
+5,000
New +$87.2K 0.01% 526

Other funds holding KDNY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Bailard's KDNY Position: Q2 2019 in Review

Bailard sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2019, closing a stake of 5,000 shares — an estimated $100K sold.

Bailard first reported a position in KDNY in Q1 2019 and held it in 1 quarter. The position peaked at $100K in Q1 2019. 97 funds tracked by Wall St. Rank hold KDNY as of Q2 2019.

  • Bailard reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Bailard sold 5,000 Chinook Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $100K.
  • Bailard first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2019 and held it in 1 quarter.
  • Bailard's Chinook Therapeutics, Inc. Common Stock position peaked at $100K in Q1 2019.
  • 97 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Bailard's 13F filing for Q2 2019, filed 26 Jul 2019.